A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose
Sponsor: Brigham and Women's Hospital
This PHASE4 trial investigates Hyperglycemia and Hypertension and is currently completed. Brigham and Women's Hospital leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jun 2022 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE4
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .